February 1st, 2024
Preclinical Characterization and Phase I Trial Results
of INBRX-109, A Third-Generation, Recombinant,
Humanized, Death Receptor 5 Agonist Antibody,
in Chondrosarcoma
Vivek Subbiah1, Sant P. Chawla2, Anthony P. Conley3, Breelyn A. Wilky4, Anthony…